These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27904739)

  • 41. Multicentric Castleman's disease in HIV patients: a single-center cohort diagnosed from 2008 to 2018.
    Gliga S; Orth HM; Lübke N; Timm J; Luedde T; Jensen BO
    Infection; 2021 Oct; 49(5):945-951. PubMed ID: 33945103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease.
    Otani K; Inoue D; Fujikura K; Komori T; Abe-Suzuki S; Tajiri T; Itoh T; Zen Y
    Oncotarget; 2018 Jan; 9(6):6691-6706. PubMed ID: 29467920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
    Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
    Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Surgery in Castleman's disease: a systematic review of 404 published cases.
    Talat N; Belgaumkar AP; Schulte KM
    Ann Surg; 2012 Apr; 255(4):677-84. PubMed ID: 22367441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicentric Castleman's disease and Kaposi's sarcoma in a cyclosporin treated, HIV-1 negative patient: case report.
    Bollen J; Polstra A; Van Der Kuyl A; Weel J; Noorduyn L; Van Oers M; Cornelissen M
    BMC Blood Disord; 2003 Dec; 3(1):3. PubMed ID: 14670091
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
    Vernon M; Robinson D; Trundell D; Ishak J; Jen MH; Brazier J
    Curr Med Res Opin; 2016 Jul; 32(7):1193-200. PubMed ID: 26972925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
    Bedier H; Isnard S; Maedler-Kron C; Routy JP
    Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A rare case of multicentric castleman's disease transforms into multiple myeloma and its successful treatment.
    Yang D; Zhou X; Zhao Y; Cao S; Su A; Zhang X; Xu Y; Zhang X
    Cancer Biol Ther; 2018; 19(11):949-952. PubMed ID: 29580142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fifty years of multicentric Castleman's disease.
    Waterston A; Bower M
    Acta Oncol; 2004; 43(8):698-704. PubMed ID: 15764213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Castleman's disease, pathophysiology, advances in diagnosis and treatment.
    Pertusa Mataix R; Loaiza Cabello D; García Morillo JS
    Med Clin (Barc); 2024 Mar; 162(6):283-290. PubMed ID: 38016855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Presentation and Outcome of Castleman's Disease in Immunocompetent Hosts.
    Prakash G; Bal A; Malhotra P; Aggarwal V; Khadwal A; Suri V; Jain S; Kumari S; Srinivasan R; Das A; Varma N; Varma S
    Indian J Hematol Blood Transfus; 2016 Dec; 32(4):468-474. PubMed ID: 27812258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura.
    Sood R; Taylor HC; Daw H
    Case Rep Hematol; 2013; 2013():269268. PubMed ID: 24198982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
    Lyseng-Williamson KA
    BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tocilizumab-effective multicentric Castleman's disease with infiltration of eosinophil and IgG
    Katsumata Y; Ikari J; Tanaka N; Abe M; Tsushima K; Yonemori Y; Tatsumi K
    Respir Med Case Rep; 2018; 25():25-29. PubMed ID: 29998054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-associated multicentric Castleman's disease.
    Naime Fde F; Fakhouri F; Martins CS; Couto WJ
    Rare Tumors; 2012 Jun; 4(3):e40. PubMed ID: 23087796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Idiopathic multicentric Castleman's disease].
    Vasilyev VI; Palshina SG; Pavlovskaya AI; Kokosadze NV; Chaltsev BD; Shornikova LA
    Ter Arkh; 2020 Jun; 92(5):78-84. PubMed ID: 32598779
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Kurzrock R
    Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases.
    Lajoie G; Kumar S; Min KW; Silva FG
    Am J Surg Pathol; 1995 Sep; 19(9):1021-8. PubMed ID: 7661275
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Siltuximab for multicentric Castleman disease.
    Liu YC; Stone K; van Rhee F
    Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multicentric Castleman's Disease and Kaposi's Sarcoma in a HIV-Positive Patient on Highly Active Antiretroviral Therapy.
    Ortega L; Cooper CJ; Otoukesh S; Mojtahedzadeh M; Didia CS; Torabi A; Nahleh Z
    Rare Tumors; 2014 Jul; 6(3):5480. PubMed ID: 25276327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.